By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Key Statistics

Email: n/a
Ownership: Public

Web Site: AmpliPhi Biosciences Corporation
Symbol: APHB


Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.

Company News
AmpliPhi Biosciences Corporation (APHB) Announces Appointment of New Board Member 5/22/2014 7:38:18 AM
AmpliPhi Biosciences Corporation (APHB) To Present At 13th Annual Needham Healthcare Conference 4/1/2014 7:17:01 AM
AmpliPhi Biosciences Corporation (APHB) To Present At Upcoming Healthcare Conferences 2/26/2014 7:18:42 AM
AmpliPhi Biosciences Corporation (APHB) Closes $18 Million Private Placement 12/26/2013 9:00:53 PM
AmpliPhi Biosciences Corporation (APHB) Announces $18 Million Private Placement 12/16/2013 8:08:26 AM
AmpliPhi Biosciences Corporation (APHB) Announces $18 Million Private Placement 12/16/2013 6:35:21 AM
AmpliPhi Biosciences Corporation (APHB) Announces The Appointment Of Baxter Phillips, III, As Vice President Of Corporate Strategy And Business Development 11/13/2013 11:00:48 AM
AmpliPhi Biosciences (TGEN) Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies 10/17/2013 9:18:41 AM
AmpliPhi Biosciences (TGEN) Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis 8/8/2013 11:13:36 AM
AmpliPhi Biosciences (TGEN) Signs Global R&D Agreement With US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections 7/1/2013 8:46:07 AM